Similarly, Zhou et al. [18] and Liu et al. [19] demonstrated that FOXO3 upregulation mediates the loss of sensitivity to doxorubicin, epirubicin, or cisplatin in HCC in vitro models. Here, FOXO3 is linked to hepatocellular carcinoma.